Vol. 8 No. 1 (2021): January-December 2021

Published: 2021-12-28

Full Issue

Vol. 8 January-December 2021

Original Research Articles

Metastatic renal cancer: real-world evidence from a large Italian claims database

1-7
- PDF (Italian)
- ePub
- html
Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain

8-13
- PDF
- ePub
- html
A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen

14-21
- PDF
- ePub
- html
The future of Funds for Innovative Medicines: results from a Delphi Study

22-28
- PDF (Italian)
- ePub
- html
Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital

29-34
- PDF
- ePub
- html
Costs of the management of hemophilia A with inhibitors in Spain

35-42
- PDF
- ePub
- html
Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy

43-52
- PDF
- ePub
- html
- PDF (Italian)
- ePub (Italian)
- html (Italian)
Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

53-57
- PDF
- ePub
- html
The Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment

58-66
- PDF
- ePub
- html
Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

69-79
- PDF (Italian)
- ePub
- html
Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus

80-86
- PDF
- ePub
- html
Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia

87-95
- PDF (Italian)
- ePub
- html
Budget Impact Analysis of prolonged-release buprenorphine depot-formulation for the management of patients affected by opioid use disorder

96-104
- PDF (Italian)
- ePub
- html
Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population

105-113
- PDF (Italian)
- ePub
- html
Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy

120-130
- PDF (Italian)
- ePub
- html
The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective

140-146
- PDF
- ePub
- html
Evaluation of epidemiological and economic consequences due to the delay in treatment of hiv-positive patients caused by the covid-19 pandemic

147-154
- PDF (Italian)
- ePub
- html
Cost-utility analysis of evolocumab in patients with ASCVD in Italy

155-167
- PDF (Italian)
- ePub
- html

Correspondence

Point of View

Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?

Claudio Jommi, Antonio Addis, Nello Martini, Elena Nicod, Marcello Pani, Annalisa Scopinaro, Sabine Vogler

114-119
- PDF
- ePub
- html
New drug pricing criteria in Italy: considerations and proposals to support value and innovation

Francesca Patarnello, Federico Villa

131-133
- PDF (Italian)
- ePub
- html
Real-world data: how they can help to improve quality of care

Giovanni Corrao, Giovanni Alquati, Giovanni Apolone, Andrea Ardizzoni, Giuliano Buzzetti, Giorgio W. Canonica, Pierfranco Conte, Elisa Crovato, Francesco Damele, Carlo La Vecchia, Aldo P. Maggioni, Alberto Mantovani, Michele Marangi, Walter Marrocco, Andrea Messori, Alessandro Padovani, Alessandro Rambaldi, Walter Ricciardi, Francesco Ripa di Meana, Federico Spandonaro, Valeria Tozzi, Giuseppe Mancia

134-139
- PDF (Italian)
- ePub
- html

Vol. 8 No. 1 (2021): January-December 2021

Full Issue

Original Research Articles

Metastatic renal cancer: real-world evidence from a large Italian claims database

Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain

A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen

The future of Funds for Innovative Medicines: results from a Delphi Study

Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital

Costs of the management of hemophilia A with inhibitors in Spain

Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy

Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

The Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment

Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus

Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia

Budget Impact Analysis of prolonged-release buprenorphine depot-formulation for the management of patients affected by opioid use disorder

Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population

Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy

The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective

Evaluation of epidemiological and economic consequences due to the delay in treatment of hiv-positive patients caused by the covid-19 pandemic

Cost-utility analysis of evolocumab in patients with ASCVD in Italy

Correspondence

Comments on "Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain"

Author’s reply to comments on “Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain”

Point of View

Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?

New drug pricing criteria in Italy: considerations and proposals to support value and innovation

Real-world data: how they can help to improve quality of care

Browse

banners150

Vol. 8 No. 1 (2021): January-December 2021

Full Issue

Original Research Articles

Correspondence

Point of View

Sign up

Browse

banners150